SEC Form 4 · accession 0001209191-19-003672
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Wayne Ward
Officer — Chief Development Officer
Period of report
Jan 14, 2019
Accepted (ET)
Jan 15, 2019 · 11:25 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF1 | Jan 14, 2019 | C | 8,620 | — | A | 8,620 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2,F1 | $11.62 | Jan 14, 2019 | M | 8,620 | D | — | Jun 15, 2023 | Class B common stock | 8,620 | 12,517 | D |
| Class B common stockF1 | — | Jan 14, 2019 | M | 8,620 | A | — | — | Class A common stock | 8,620 | 8,620 | D |
| Class B common stockF1 | — | Jan 14, 2019 | C | 8,620 | D | — | — | Class A common stock | 8,620 | 0 | D |
Explanation of responses
- F1The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F2The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.